Journal Home
Search for

Volume 19, Issue 7, Pages 462-468 (September 2009)


View previous. 4 of 12 View next.

Obesity markers and estimated 10-year fatal cardiovascular risk in Switzerland

P. Marques-VidalabCorresponding Author Informationemail address, M. Bochudb, V. Mooserc, F. Paccaudb, G. Waeberd, P. Vollenweiderd

Received 18 June 2008; received in revised form 3 October 2008; accepted 6 October 2008. published online 30 January 2009.

Abstract 

Background and aim

There is an ongoing debate on which obesity marker better predicts cardiovascular disease (CVD). In this study, the relationships between obesity markers and high (>5%) 10-year risk of fatal CVD were assessed.

Methods and results

A cross-sectional study was conducted including 3047 women and 2689 men aged 35–75years. Body fat percentage was assessed by tetrapolar bioimpedance. CVD risk was assessed using the SCORE risk function and gender- and age-specific cut points for body fat were derived. The diagnostic accuracy of each obesity marker was evaluated through receiver operating characteristics (ROC) analysis.

In men, body fat presented a higher correlation (r=0.31) with 10-year CVD risk than waist/hip ratio (WHR, r=0.22), waist (r=0.22) or BMI (r=0.19); the corresponding values in women were 0.18, 0.15, 0.11 and 0.05, respectively (all p<0.05). In both genders, body fat showed the highest area under the ROC curve (AUC): in men, the AUC (95% confidence interval) were 76.0 (73.8–78.2), 67.3 (64.6–69.9), 65.8 (63.1–68.5) and 60.6 (57.9–63.5) for body fat, WHR, waist and BMI, respectively. In women, the corresponding values were 72.3 (69.2–75.3), 66.6 (63.1–70.2), 64.1 (60.6–67.6) and 58.8 (55.2–62.4). The use of the body fat percentage criterion enabled the capture of three times more subjects with high CVD risk than the BMI criterion, and almost twice as much as the WHR criterion.

Conclusion

Obesity defined by body fat percentage is more related with 10-year risk of fatal CVD than obesity markers based on WHR, waist or BMI.

a Cardiomet, CHUV, Lausanne, Switzerland

b Institute of Social and Preventive Medicine (IUMSP), University of Lausanne, Lausanne, Switzerland

c Medical Genetics, GlaxoSmithKline, Philadelphia, PA, USA

d Department of Medicine, Internal Medicine, CHUV, Lausanne, Switzerland

Corresponding Author InformationCorresponding author. Institute of Social and Preventive Medicine (IUMSP), Centre Hospitalier Universitaire Vaudois and University of Lausanne, Bugnon 17, 1005 Lausanne, Switzerland. Tel.: +41 21 314 7272; fax: +41 21 314 7373.

PII: S0939-4753(08)00204-4

doi:10.1016/j.numecd.2008.10.001


View previous. 4 of 12 View next.